Novartis Misses in the Exact Shape It Guided, While Net Debt Adds $16 Billion in Ninety Days

Results vs. Consensus

Novartis is a Swiss foreign private issuer reporting under IFRS. Its primary operating measure is "core" (non-IFRS) results and it guides in constant currencies. Every figure below traces to the April 28 media release and the accompanying Condensed Interim Financial Report; growth rates are as the company presents them, with the currency basis labelled wherever it matters. One convention is worth stating because it inverts the usual reading: in the company's percentage-change columns, a reduction in an operating expense is shown as positive growth, so a "-17%" against core R&D means the expense rose.

Q1 2026 Scorecard

Consensus for core EPS reads $2.10 to $2.11 across the sources we track, and for net sales $13.4B to $13.6B, a spread of roughly $200M that is wide enough to be worth quoting as a range rather than a point. On the narrowest read the sales shortfall is 2.1%; on the widest it is 3.6%. Where no reliable consensus exists for a line, the column reads "n/a" rather than a manufactured number. The core operating income comparison rests on a single analyst poll and should be read as an estimate rather than a firm consensus.

Q1 2026 vs. Q1 2025

Q1 2026 vs. Q4 2025

Quality of Beat/Miss

• Revenue: The company's bridge decomposes cleanly. Volume contributed thirteen points of growth, generic competition took fourteen back, pricing cost four (of which a net one point is US revenue-deduction adjustments lapping a favourable prior-year quarter), and currency added four. Thirteen points of volume growth in a quarter that printed -5% cc is the operating business; the print is the loss-of-exclusivity cohort sitting on top of it. Where the miss becomes a genuine miss is Entresto, at $1,305M against a $1.37B expectation, down 46% cc with US sales down 94% to $72M. Erosion that steep is not a modelling nuance, it is a curve the Street had drawn too shallow.
• Margins: Higher quality than the 480bps decline suggests. Core gross margin fell 154bps to 82.2% of net sales on generic mix, while core R&D rose 322bps to 20.6% of net sales from 17.4%. The CFO's own decomposition of the 410bps cc decline puts three points on R&D and one on the generic hit to gross margin, which reconciles. Core SG&A rose only 82bps as a share of sales despite the smaller denominator, and lower core other expense returned about 53bps. Nothing here is a one-time flatter or a one-time hole.
• EPS: Core net income fell 15.4% while core EPS fell 12.7%. The 2.7 point gap is the buyback: weighted average basic shares of 1,909M were 3.0% below the prior year. Below the operating line, core interest expense of $343M rose from $270M on higher financial debt, and the core tax rate of 16.7% ran 20bps above the 16.5% full-year guide. The IFRS EPS decline of 11% cc is smaller than the core decline because core adjustments fell to $662M from $912M, helped by $125M of divestment gains that do not repeat.

Segment Performance

Novartis reports net sales by core therapeutic area and by region rather than by operating segment. Both cuts are given below. The therapeutic-area table is the one that matters for the thesis, because it isolates how much of the company is now growth portfolio and how much is still the eroding base.

Net sales by core therapeutic area

Net sales by region

The priority growth cohort

Our coverage tracks a six-brand cohort established at initiation. Novartis's own "growth drivers" headline changed definition this quarter, and the difference is large enough that the two numbers should not be used interchangeably.

The eight-brand cohort's 38% USD growth reconciles to the headline +34% cc after the four-point currency tailwind. Adding a $1,566M brand growing -2% cc to a cohort growing 56% is not wrong, but it changes what the number measures, and the number is the one management leads with on slide four. Our six-brand series is the continuous one: 21.2% of net sales in Q1 2025, 30.3% in Q4 2025, 33.4% now.

Oncology

Oncology became the largest therapeutic area this quarter at $4,021M and 30.7% of net sales, up from 21.8% a year ago, on 35% cc growth. Kisqali carried it, adding $560M of USD growth on its own to reach $1,516M, with US sales up 58% and ex-US up 50% cc. The share data underneath is the part that matters more than the dollars: US new-to-brand share in early breast cancer stands at 65%, two points higher than the prior quarter, with 47% new-to-brand and 41% total prescriptions in metastatic. Germany is approaching 80% share in early breast cancer, the UK 78%. The brand is now launched in 69 countries and reimbursed in 40, which is the runway.

Pluvicto grew 70% cc to $642M with more than 70% of US business now in the pre-taxane setting and over 60% of new patients coming from community rather than academic centres. Scemblix grew 79% cc to $433M and moved US first-line new-to-brand share to 31% from the mid-20s where it sat at year-end, with 42% share across all lines and a 50% first-line new-to-brand share in Japan. Fabhalta more than doubled to $169M with new-to-brand leadership in both paroxysmal nocturnal hemoglobinuria at 50% and C3 glomerulopathy at 56%.

"When we look at that data in more detail, we see that Kisqali has a strong position, not only in the overlapping segment with our competitor in early breast cancer, but also in our unique segment, particularly the node one high risk and the node zero high risk patients." — Vas Narasimhan, CEO

Assessment: This is the segment doing the work the thesis was underwritten on, and the share data says the growth is share capture rather than market expansion, which is the more durable kind. The Scemblix move off the mid-20s toward the stated 40% to 50% first-line ambition was one of the specific things we said in February we would be watching, and it delivered.

Neuroscience

Neuroscience grew 16% cc to $1,561M on Kesimpta at $1,164M, up 26% cc, with US total prescriptions up 21% and roughly two points ahead of the market. New-to-brand share reached 17% of the whole multiple sclerosis market and 28% of the B-cell class. Ex-US growth of 31% cc is the faster half, with management estimating one in six European multiple sclerosis patients now on the drug and new-to-brand leadership in nine of ten major markets. Zolgensma Group fell 12% cc to $302M on lower spinal muscular atrophy incidence and treatment phasing, which is the structural feature of a one-time gene therapy in a screened population rather than a share loss.

Assessment: Kesimpta's ex-US growth outrunning its US growth is the more interesting half of this line, because it means the runway is geographic rather than purely competitive, and two-thirds of disease-modifying-therapy patients in the key markets are still not on a B-cell agent. The every-two-month dosing readout next year is the next catalyst for the franchise and it is not in anyone's numbers.

Immunology

Immunology was flat, at $2,466M and -1% cc, which is Cosentyx doing nothing. Cosentyx printed $1,566M, up 2% in USD and down 2% cc, with US sales down 6% and ex-US up 3% cc. The decline is not demand: the prior-year quarter carried a favourable US revenue-deduction adjustment, and excluding those effects on both sides the company puts underlying global growth at 2% cc and US growth close to 1%. Hidradenitis suppurativa new-to-brand share among naive patients sits around 50% after a January dip management attributes to reverification and biosimilar availability, and intravenous patient share has climbed to 14%. Ilaris grew 10% cc to $475M. Xolair fell 20% cc to $388M. Rhapsido, the remibrutinib brand, contributed its first $37M.

"We continue to see competitive pressures in China, with multiple local NRDL entrants. There's a long list of competitors that we have. We've had very strong share performance in China now over many years. Our goal will be to maintain now share and hopefully can stabilize as well the performance in China over the coming quarters." — Vas Narasimhan, CEO

Assessment: Cosentyx is the brand where the gap between the reported number and the underlying number is widest, and it is also the brand where management declined to restate a peak-sales figure when asked directly. A franchise growing 2% underlying, facing a 2028 pricing event and a 2029 US exclusivity loss, carrying $8B of peak-sales expectation that was not repeated, is the single largest unresolved item in the near-term model.

Cardiovascular, renal and metabolic

This is where the cliff lives. The area fell 33% cc to $1,773M because Entresto fell 46% cc to $1,305M, and inside that, US Entresto fell 94% to $72M while ex-US grew 6% cc to $1,233M. The US brand is effectively gone, one year after generics entered. Leqvio is the offset and it is growing fast rather than merely growing: $452M at +69% cc, with US growth of 31% and ex-US growth of 106% cc driven by the January National Reimbursement Drug List listing in China. Vanrafia contributed $16M in its launch quarter with roughly 11% US new-to-brand share.

Assessment: The Entresto US line reaching $72M removes almost all remaining downside from that specific brand, which is genuinely useful: the largest single erosion in the company's history is now nearly complete and its residual drag on 2027 is small. The offsetting caution is that management characterised the China Leqvio surge as possibly a bolus rather than steady demand, in their own words needing "the coming quarters" to distinguish the two.

Established brands

Established brands fell 24% cc to $3,292M, or 25.1% of net sales from 31.1% a year ago. Promacta/Revolade fell 68% cc to $184M with US sales down 91% to $25M, and Tasigna fell 61% cc to $155M with US sales down 86% to $28M. Lucentis fell 50% cc to $104M. Contract manufacturing was $352M. Management put the full-year 2026 generic sales loss at roughly $4B.

Assessment: The three named loss-of-exclusivity brands are now largely through their US erosion, which is what makes the second-half base comparison mechanically easier. The item worth tracking is the drift beyond the named three, which spans therapeutic areas: Xolair at -20% cc, Tafinlar plus Mekinist at -14% cc, Sandostatin at -12% cc and Kymriah at -22% cc are not part of the cliff narrative and are collectively larger than Promacta and Tasigna combined.

Key KPIs

A caution on reading the Rhapsido numbers as revenue: the launch is running on sampling and bridge programmes, so scripts and sales are deliberately decoupled this year. Management said the conversion from free to paid will be stepwise across 2026 with the acceleration in 2027.

Key Topics & Management Commentary

Overall Management Tone: Management was procedural rather than defensive, treating a miss on every headline line as a scheduling matter and spending the bulk of the prepared remarks on launch share data and second-half readouts. Analyst pushback was almost entirely clinical rather than financial: nineteen questions produced seven on one molecule and none on the balance sheet, which says as much about where the buy side's attention sits as about the call itself. The one place the posture shifted versus February was on US pricing policy, where the tone moved from acknowledging an unquantified overhang to declaring the topic settled enough to drop from the slides.

1. The generic wave arrives on schedule, and it is steeper than modelled

Three US exclusivity losses define this year's base: Entresto from the third quarter of 2025, Tasigna and Promacta from the second. Q1 2026 is the first quarter to lap none of them, which is why generic competition took fourteen points off growth. The company put the full-year sales loss from generics at roughly $4B. What the print added to what February already told us is the depth of the curve rather than its shape: US Entresto fell 94% to $72M, and the resulting $1,305M total came in below the $1.37B the Street carried.

"Our Q1 results, as expected, were impacted by U.S. GX erosion, with sales down 5% and core OpEx down 14%. Worth noting is that we did have a positive gross net in our base from Q1 last year that also had a negative impact on the overall quarterly growth rate. Core margin in Q1 declined 4.1%. This was mainly due to higher R&D investments as well as the impact of generics on the gross margin. These results were fully in line with our internal expectations and how we see 2026 P&L phasing through the year panning out." — Mukul Mehta, CFO

Assessment: A company that guides a trough and then delivers the trough has not disappointed, but it has also not earned anything. The useful fact is that the US Entresto line is now small enough that its remaining downside is immaterial, which pulls a known risk forward out of 2027.

2. The R&D step-up, and the quarter it stops compounding

Core R&D of $2,704M was 20.6% of net sales against 17.4% a year ago, and it is the single largest contributor to the margin decline. The composition matters more than the level. Four transactions drive it: Avidity, which closed inside the quarter and contributed one month, plus Tourmaline, Anthos and Regulus, all of which entered the profit and loss account from the second quarter of 2025. Q1 2026 is therefore the last quarter in which all four are fully incremental to the prior-year comparison.

"In Q1, all of these 3 deals plus 1 month of Avidity is incremental. Going forward, I think part of it is already in the base." — Mukul Mehta, CFO

Assessment: This is the mechanical half of the second-half inflection and it is more reliable than the revenue half, because it depends on arithmetic rather than on launches landing. It also means the 480bps margin decline should be read as a peak rather than a run-rate, and a reader modelling Q1's margin forward through 2026 will be materially too low.

3. Rhapsido: a launch measured in prescribers rather than dollars

Remibrutinib, launched as Rhapsido in chronic spontaneous urticaria, contributed $37M and 3,000 prescribers, 6,000 patient starts and an estimated 24% new-to-brand share. Management was explicit that the revenue line is not the signal this year because the launch is running on free-drug and bridge programmes while payer coverage builds, with early wins across several large commercial plans securing first-line coverage after antihistamines.

"We are having early access wins, but I would say that access will build over the course of the year. It will take us the full year to get to where we want to ultimately get to from an access standpoint. That'll be important as well because that's what allows us to bridge from free drugs to ultimately paid scripts. That'll be a steady uptake over the course of the year, not a fast inflection." — Vas Narasimhan, CEO

The pipeline stacked behind the brand moved forward on three fronts in the quarter: a positive CHMP opinion in chronic spontaneous urticaria, a positive Phase III in chronic inducible urticaria clearing all three of the most prevalent subtypes, and Phase II food-allergy data showing 86.7% responders at the 100mg dose, with 75mg twice daily selected for Phase III on modelling grounds. The hidradenitis suppurativa programme was pulled forward into the second half.

Assessment: Management has pre-emptively managed down the 2026 revenue expectation for its most important launch while raising the indication count behind it, which is the right sequence and an uncomfortable one for anyone who needs the brand to contribute this year. The risk is that a launch explained as deliberately slow is indistinguishable, from outside, from a launch that is simply slow.

4. Pelacarsen: the same words, a slightly different window

The cardiovascular outcomes readout is the single largest binary in front of this company, and management added no new information. In February the readout was framed for mid-2026. Here it is framed as the early part of the second half, described as unchanged. The powering was reconfirmed without alteration: 20% relative risk reduction in patients at or above 70 mg/dL and 25% at or above 90 mg/dL, against a median enrolled level of 108 mg/dL.

"I don't think I have anything new to add, unfortunately, because we don't have any new information. I think we, of course, continue to make sure that the study is on track. No change in our expected readout. We do expect a readout in the early part of the second half of the year." — Vas Narasimhan, CEO

The commercial framing was more revealing than the timing. Management described a positive result as launchable "regardless of the relative risk reduction," said the search would be for a pre-specified or other subgroup showing significant benefit, and characterised the category as "a slow-building market simply because we need the testing rates to get much higher." A once-yearly follow-on injectable is described as ready to enter Phase III.

Assessment: Between February and April the language moved from a mid-year readout to an early-second-half readout while the description of it moved from "no change" to a defence of why a weak win would still be commercial. Neither shift is large. Both point the same direction, and a reader should discount the headline outcome rather than the franchise.

5. Pluvicto: a European regulatory retreat with a stated path back

Novartis withdrew its EMA type II variation for Pluvicto in pre-chemotherapy PSMA-positive metastatic castration-resistant prostate cancer after CHMP feedback that the application would not be supported. The company was clear the objection concerns the comparator arm rather than quality, efficacy or safety, and that the same PSMAfore study supported approval in the US, Japan and China. Management chose not to run additional trials and instead to re-enter Europe through the hormone-sensitive setting, where the comparator design is one the regulator accepts.

"We had assumed all along that navigating the European feedback on the comparator arm would be, you know, a challenge. We evaluated multiple ways to try to address it, and we tried to make the best arguments that we could, but ultimately we thought it was prudent at that point to withdraw." — Vas Narasimhan, CEO

Peak sales guidance was left at $5B or better, and the hormone-sensitive approval expected in the second half is described as expanding the eligible pool by 75%.

Assessment: A withdrawal that costs no peak-sales revision is a withdrawal that was already in the model, and the disclosure was handled well. The residual concern is timing rather than size: Europe now waits on overall-survival data from a different trial, which pushes a meaningful share of the pool out by years rather than quarters.

6. Most-favoured-nation pricing leaves the slide deck

The single largest change in disclosure this quarter was a subtraction. The policy line that appeared on the equivalent guidance slide in February is absent here, and the last question of the call asked why.

"We also have signed the agreements to allow us to not have an impact from tariffs, with the commercial agreement that we’ve signed with the U.S. government, as well as scaling up, as you’ve seen, our manufacturing plants around the U.S. to allow us to produce fully in the U.S. for the U.S. such that we wouldn’t expect any tariff impact. All that to say, I guess at this point we feel confident enough with MFN that we don’t need to mention it anymore. Hence, that’s why you’re not seeing it on the slides." — Vas Narasimhan, CEO

Two genuinely new mechanical disclosures came with it. Rhapsido carries a policy impact only through Medicaid, because its approval predated the signing of the company's agreement with the US government, and the same treatment is expected to extend to subsequent remibrutinib brands and to the intrathecal Zolgensma formulation on the logic that the underlying compound is what is captured. The first launch expected to carry the full effect across all US reimbursement segments is ianalumab. Separately, management said tariff exposure is addressed through the commercial agreement signed with the US government and through US manufacturing scale-up.

Assessment: This is the first specific, checkable statement we have had about how the policy attaches to individual assets, and it is worth having. It does not, however, answer the question we set in February, which was magnitude. A company that removes a risk from its slides while still declining to quantify it has changed its presentation rather than its disclosure, and the burden of proof for that move sits with the second half.

7. European launch pricing: the clarification that has not arrived

In February management promised to clarify ex-US launch pricing strategy under the new policy regime "over the course of this year." Asked directly whether European governments are inclined to pay more for innovation, the answer was candid and negative.

"We are engaging, you know, with governments across Europe as well as in Japan to hopefully get to a better place. I think we're not seeing the progress that we had hoped to see at the pace that we had hoped to see." — Vas Narasimhan, CEO

The framing extended to a warning about the industry rather than the company: management noted that 30% to 40% of medicines available in the US never reach Europe, that the number could grow, and that "it's really a 2027 story where you start to see the impact of MFN on launches in Europe."

Assessment: This is the second consecutive quarter in which the promised clarification has not been delivered, and the reason has shifted from a work-in-progress framing to an explicit statement that the counterparties are not moving. That is a worse answer than no answer, because it converts a disclosure gap into a negotiating failure with a named deadline a year out.

8. Avidity closes, and the capital allocation bill comes due

The Avidity acquisition completed inside the quarter, adding three late-stage neuromuscular programmes. The quarter also carried announcements of two further early-stage transactions: Synnovation's pan-mutant selective PI3K-alpha inhibitor for breast cancer, expected to close in the first half, and Excellergy's half-life-extended anti-IgE antibody, expected to close in the second. Total M&A and intangible cash outflow in the quarter was $12.5B.

"We remain committed to our balanced, shareholder-friendly capital allocation strategy alongside an increased R&D. In the first quarter, we closed the Avidity acquisition. We also announced two early-stage deals to support our oncology and immunology disease franchises." — Mukul Mehta, CFO

Assessment: The deals themselves are defensible and consistent with a company replacing a large expiring base. What is no longer defensible is describing the resulting allocation as "balanced" without addressing the funding, which is the subject of the next topic and was not raised on the call.

9. Net debt: sixteen billion dollars in ninety days

Net debt reached $38,087M at March 31 against $21,947M at December 31 and $22,271M a year earlier. Total financial debt rose to $45,064M from $33,537M, and total liquidity fell to $6,977M from $11,590M. The bridge is not mysterious: $12.5B of M&A and intangible outflows, the $6.2B net dividend paid in March (the $9.1B gross dividend less $2.9B of Swiss withholding tax due in April), and $1.9B of treasury-share purchases, against $3.3B of free cash flow.

Set against trailing twelve-month core operating income of roughly $21.2B, net debt has moved from about 1.0x to about 1.8x in a single quarter. The buyback arithmetic underneath is its own small story. The company repurchased 10.4 million shares for $1.6B on the SIX second trading line and a further 2.0 million from employees, then delivered 12.3 million shares into equity-based compensation, finishing with shares outstanding down 0.1 million versus December 31. Roughly $6.1B remains of the up-to-$10B programme running to the end of 2027.

Assessment: This is a company whose credit ratings, Aa3 and AA-, comfortably support the leverage, so the issue is not solvency. It is that per-share growth has been carrying the earnings line for two years and the buyback just spent $1.9B of cash to reduce the share count by 0.1 million. In a year when core operating income falls, that lever mattering less is not a detail. It went unremarked by fourteen analysts.

10. Cosentyx: the exclusivity clock, the pricing event, and the number that went missing

Asked whether profitability optimisation had begun ahead of the loss of exclusivity, the CFO gave the most specific forward statement of the call.

"I think, as we have previously indicated, I think we've projected an LOE in the U.S. for Cosentyx in 2029. There is also an IRA event in 2028 that we have factored into our numbers. This is all baked into our back to 40% latest by 2029 guidance on the margin." — Mukul Mehta, CFO

A separate question asked management to reconfirm the $8B peak-sales figure for the brand, noting its absence from the release and the slides. The answer restated a mid-single-digit growth expectation globally and added that peak sales would most likely fall in 2027 given the 2028 pricing event, but did not restate the $8B.

Assessment: Confirming a 2029 US exclusivity loss and a 2028 pricing event as inputs to the 2029 margin target is useful and new. Declining to reconfirm the peak-sales number when asked directly, in the same call, is the more informative half of the exchange. The two together imply the brand peaks in 2027 at a level management no longer wishes to name.

11. China stabilises without recovering

China sales were $1.3B, up 13% in USD and 8% cc, with the Leqvio National Reimbursement Drug List listing in January the visible driver. Management's characterisation of the market was more measured than the growth rate.

"Overall, the dynamics in China, we've seen a stabilization in the early part of this year. I don't think we're back to the pre-2025 growth levels, but we do see a stabilization overall in the market as well and in our key segments. We feel confident that our China business can be in that high single-digit to low double-digit growth range." — Vas Narasimhan, CEO

On Leqvio specifically, management said the listing "unlocked significant demand" but that it is early days and the coming quarters are needed to understand how much was a bolus rather than steady demand, and set the long-run ambition at making Leqvio as large as or larger than Entresto across its indications.

Assessment: A high-single to low-double-digit China growth range is a real downgrade from the pre-2025 trajectory and management said so plainly, which is more useful than a bullish framing would have been. The Leqvio bolus caveat is the one to carry: an ex-US growth rate of 106% cc that management itself will not underwrite is not a run-rate.

12. The second-half inflection: what has to be true

The whole of the reaffirmed guidance rests on a base effect plus a launch effect. The base effect is mechanical and already visible. The launch effect is not.

"In half two, the impact of the U.S. generic entries in the base will start to minimize. This will allow strong growth of our priority brands and launches to show through the overall P&L. Hence, we continue to expect H2 sales growth of mid-single-digit and core operating growth of mid-to-high single-digit." — Mukul Mehta, CFO

Assessment: Two of the three components are close to arithmetic: the generic base rolls off and the R&D comparison eases from Q2. The third, mid-single-digit second-half sales growth, requires the priority brands to keep compounding at something close to the current rate on a base that grows every quarter. Nothing in this quarter argues against it. Nothing in this quarter proves it either, which is why the guide was reaffirmed rather than raised.

Guidance & Outlook

Nothing moved, which in a quarter that missed on three lines is itself the message. The only new numbers are the quarterly shape for Q2 and the roughly $4B full-year generic loss, and both are consistent with what February implied rather than corrections to it.

Implied half-over-half ramp: with Q1 core operating income down 14% cc and Q2 guided to decline high-single to low-double digit, the first half lands around a 12% to 13% cc decline. That is inside the guided low-double-digit range, at its deeper end rather than better than it. Getting from there to a low-single-digit full-year decline requires the second half to deliver at the upper end of its own guided mid to high single-digit growth range, because the first half is the larger of the two halves of the 2025 base: Q1 2025 core operating income of $5,575M was 13% larger than Q4 2025's $4,929M. The guidance is internally consistent and it leaves essentially no slack. A second half at the bottom of its own range puts the full year at the bottom of the annual range rather than through it.

Street at: consensus entering the print sat around $2.11 of core EPS for the quarter and roughly $5.1B of core operating income, both of which proved 4% to 6% too high. Because the annual guide was reaffirmed rather than trimmed, a Street that cuts Q1 and holds the year has to raise the second half, which is the mechanically awkward position the reaffirmation creates. We would expect full-year core EPS estimates to settle in the $8.60 to $8.90 range we set in February rather than to move materially.

Guidance style: this management team raised guidance twice during 2025 and delivered at or above the raised range both times. Applied here, a reaffirmation after a three-line miss is a stronger signal than it looks, because the same team would ordinarily have used the opportunity to reset expectations lower if the second half were in doubt. The counter-argument is that the CFO is one quarter into the job and a first-quarter reset is the one thing a new CFO cannot do cheaply.

Analyst Q&A Highlights

Nineteen questions across two rounds, from fourteen firms. The distribution is the story: seven questions touched remibrutinib in one indication or another, six went to pipeline readouts and their handicapping, and none went to the balance sheet.

The free-to-paid bridge on the flagship launch

A recurring line of questioning pressed on whether the early revenue from the chronic spontaneous urticaria launch reflected genuine demand or channel stocking, and whether the previously flagged step-up in the second quarter still holds. Management separated the two cleanly, said stocking was normal, and reframed the year as a coverage-building exercise rather than a revenue one.

Q: "The previous communication was that we should see limited sales in Q4 last year, Q1 this year, because of the free scripts, before we see a step-up in Q2. Actually we saw quite decent sales in the first two quarters. I guess question is how much stocking have we seen so far? Should we still expect a step-up in Q2 as we bridge to paid script?"
— Thibault Boutherin, Morgan Stanley

A: "I would say first on stocking, we've seen stocking levels that are, you know, in line with what we've seen historically for brands. I don't think there's a significant anything that's out of what we would expect from a stocking perspective. I think when you look at the early data, as I mentioned, 6,000 patient starts, 3,000 prescribers, about a quarter of the top CSU physicians prescribing the medicine. That's all, I think, in the right direction. We think that the early script data probably has to be interpreted, you know, carefully because we are using sampling and bridge programs. As payer coverage expands, we will start to see the conversion from free to paid, but that's gonna be a stepwise process over the course of the year."
— Vas Narasimhan, CEO

Assessment: Management answered the stocking question and then moved the goalposts on the revenue question, deferring the acceleration to 2027. That is probably the right operational call and it is unambiguously a reduction in what 2026 can contribute from the most important launch in the portfolio. The metric to hold them to is coverage, not sales.

Confidence and timing on the cardiovascular outcomes readout

The largest single binary in the story drew a direct request for an updated confidence level. Management declined to provide one and reconfirmed the trial's design assumptions without alteration, which is the correct answer from a blinded sponsor and an unsatisfying one for anyone sizing the event.

Q: "Taking up on your offer, Vas, could you give us your updated levels of confidence on the timing and outcome of the pelacarsen HORIZON study?"
— Simon Baker, Rothschild & Co

A: "I don't think I have anything new to add, unfortunately, because we don't have any new information. I think we, of course, continue to make sure that the study is on track. No change in our expected readout. We do expect a readout in the early part of the second half of the year. No change with respect to that. I think if we get a positive result overall, that regardless of the relative risk reduction, we'll find a way to ultimately launch the medicine."
— Vas Narasimhan, CEO

Assessment: The phrase to carry forward is "regardless of the relative risk reduction." A sponsor that pre-commits to launching whatever the effect size is telling you it expects a range of outcomes wide enough to include a commercially awkward one. The powering, 20% at or above 70 mg/dL and 25% at or above 90 mg/dL against a median enrolled level of 108, remains the only quantified anchor available.

European launch pricing after the US agreement

The most substantive policy exchange of the call asked whether European governments are showing any willingness to pay more for innovation now that US prices are constrained. The answer was the clearest statement yet that the ex-US half of the policy trade is not working.

Q: "My question's about Rhapsido. First, now that we're heading to EU approval, Rhapsido is gonna be one of the first pricing discussions for a multi-billion dollar product since MFN. Assuming that you've had some early discussions with European governments, are you seeing countries inclined to pay higher prices for innovation in Europe?"
— Matthew Weston, UBS

A: "We are engaging, you know, with governments across Europe as well as in Japan to hopefully get to a better place. I think we're not seeing the progress that we had hoped to see at the pace that we had hoped to see. I think there has to be some urgency here, because I do expect across the industry there will be difficult decisions companies will have to take in terms of how they launch or ultimately progress, you know, medicines."
— Vas Narasimhan, CEO

Assessment: This is a negative answer given plainly, which is to management's credit and to the thesis's detriment. February's commitment was to clarify ex-US launch pricing during the year; two quarters in, the clarification is that the counterparties are not moving and the effect lands in 2027.

Why the policy line disappeared from the guidance slide

The final question of the call was the sharpest, noting that the equivalent slide in the previous quarter's deck carried a reference to the pricing regime and this one does not.

Q: "Slide 25 no longer mentions MFN, whereas the same slide in the Q4 deck did. I am just curious why. I heard your earlier responses to Matthew's questions, slide 25 suggests that Novartis is increasingly confident in its ability to deal with MFN, and I am just wondering what has changed as we start 2026."
— Steve Scala, TD Cowen

A: "No change in our perspective on MFN. I mean, we’ve fully factored in MFN into the guidance that we’ve given both for this year and the 5-year period. That’s fully factored. If anything, I think we’ve gotten even better now at modeling the MFN impact. We’ve made clear assumptions on the impact on the existing portfolio of medicines for the Medicaid effect, as well as on future launches, a set of assumptions on launch phasing for drugs that have a full MFN effect." … "All that to say, I guess at this point we feel confident enough with MFN that we don’t need to mention it anymore. Hence, that’s why you’re not seeing it on the slides."
— Vas Narasimhan, CEO

Assessment: The answer is internally coherent and it still leaves the reader unable to size the item. "Fully factored" is an assurance, not a disclosure, and it is now the second consecutive quarter in which the magnitude has been withheld while the framing has grown more confident. Removing a risk from the slides is a presentational decision; the quarter it becomes visible in the numbers will be a different conversation.

The composition of the margin decline

The one financial question of substance asked whether the gross-margin pressure carries a scale component or is purely mix. The response produced the most useful piece of modelling guidance on the call.

Q: "The gross margin is pressured by negative mix effect. Obviously, that is partly driven by the generic erosions and partly by the new products having payaways. Is there a scale factor in here that we should take into consideration as we think about the first half, second half of the year? Or is the gross margin just plain and simple mix-driven?"
— Michael Leuchten, Jefferies

A: "If we look at Q1, the overall decrease in the margin is 4.1%. 3 percentage points of that comes from R&D spend, and 1 percentage point comes from the GX impact on gross margin. GX impact on gross margin, pretty much I think if we take 2025 as a base, pretty much H2 base is what you guys should model going into this year, and that should be the base."
— Mukul Mehta, CFO

Assessment: This is the answer that makes the second-half guide modellable. The generic hit to gross margin is a level, not a trend, and the 2025 second-half gross margin is the base to carry. Three of the four points of decline are an R&D choice that partially anniversaries from the next quarter. A reader who extrapolates Q1's 37.3% forward will be too low on the year.

The exclusivity clock on the second-largest brand

A question on whether profitability optimisation had begun ahead of the loss of exclusivity produced dates that had not previously been stated this precisely on a results call.

Q: "Just one please on Cosentyx. As we think about the margin impact of the Cosentyx LOE, is it fair to assume that you've already started optimizing the profitability of Cosentyx, as would be typical, ahead of any other LOE?"
— Naresh Chouhan, Intron Health

A: "Yeah, absolutely. I would confirm that. I think, as we have previously indicated, I think we've projected an LOE in the U.S. for Cosentyx in 2029. There is also an IRA event in 2028 that we have factored into our numbers. This is all baked into our back to 40% latest by 2029 guidance on the margin."
— Mukul Mehta, CFO

Assessment: Confirming that the 2029 margin target already absorbs both a 2028 pricing event and a 2029 exclusivity loss on the company's second-largest brand raises the credibility of that target considerably. It also explains why the target is 2029 rather than sooner, and why nobody should expect the margin to retrace toward 40% on the way there.

Where the second-half upside would come from

The closing slide of the prepared remarks promised readouts that "could raise" the mid to long-term growth outlook, and a question asked management to name them. The list was specific and the framing was about un-probabilising rather than about new information.

Q: "On your last slide, you highlighted that there will be multiple readouts in H2 that could raise your midterm to long-term growth outlook. Maybe, Vas, could you be a little bit more specific and give us a bit more color or on from where do you see the potential upside coming from?"
— Florence Aspedes, ODDO BHF

A: "When you look at what we guided to last fall, I mean our focus was very much on what we had in hand and a probabilized view of our pipeline. I think when then some of these medicines, if they ultimately come forward and we un-probabilize, that can lead to, you know, significant upsides versus where we are today."
— Vas Narasimhan, CEO

Assessment: The mechanism is honest and it cuts both ways. A guidance framework built on probability-weighted pipeline outcomes rises when assets read out positively and falls when they do not, and this quarter already saw one programme fail outright and another miss its primary statistical threshold. The un-probabilising argument is only a bull argument if the hit rate is above the weighting.

The competitive threat to the largest growth brand

A question on whether an emerging oral hormonal therapy could displace CDK4/6 inhibitors in adjuvant breast cancer went at the single asset the thesis depends on most. Management rejected the substitution framing and pointed to its own combination work with the competing class.

Q: "Based on what you know about hormonal breast cancer, do you think that's plausible? Do you think is it even from the end of this year, you could see some pressure on CDK4 use because people instead would just do a SERD?"
— James Gordon, Barclays

A: "We don't see that in the same way. I mean, what we expect, continue to expect is that physicians will want to use something to ultimately impact the hormonal access and then subsequently the cell cycle-dependent kinase access, especially for patients that we're talking about here, which are patients that are node 0, node 1, node 2 or more and have other risk factors that indicate they have a higher risk of recurrence of breast cancer."
— Vas Narasimhan, CEO

Assessment: The strongest part of the answer was not the clinical argument but the commercial observation that the competing oral class is partnering with Novartis on combination studies, which is behaviour inconsistent with a displacement thesis. The weaker part is that management explicitly declined to comment on lower-risk early breast cancer, which is where a substitution effect would most plausibly begin.

What They're NOT Saying

1. Anything about the balance sheet, because nobody asked: net debt rose $16.1B in ninety days to $38.1B, liquidity fell 40%, and across nineteen questions from fourteen firms not one addressed net debt, the buyback pace, free cash flow or leverage. Management volunteered a capital-allocation slide describing the strategy as balanced and was not pressed on it.
2. The buyback's actual effect on the share count: the release discloses that $1.9B of cash left the company for treasury shares and that shares outstanding fell 0.1 million versus December 31. Neither the prepared remarks nor the Q&A connected those two facts, and the per-share cushion that has carried earnings growth for two years is quietly thinner.
3. The Cosentyx peak-sales figure: asked directly whether the previously stated $8B peak still stands, and told it was absent from both the release and the slides, management answered on growth rate and peak timing without restating the number.
4. The Kisqali peak-sales figure: the $10B ambition for the company's fastest-growing brand was not mentioned in the release, the deck or the call, in a quarter when the brand grew 55% cc and passed $1.5B.
5. The five-year growth algorithm: the 5% to 6% 2025 to 2030 sales CAGR that anchored the February guide does not appear in this release. It was referenced only obliquely, as something upside readouts might allow the company to "reevaluate."
6. The magnitude of the US pricing concession: two quarters after the agreement, the effect remains "fully factored" into guidance and unquantified, and it has now been removed from the guidance slide entirely.
7. Whether the readout window moved: February framed the cardiovascular outcomes readout as mid-2026 and April frames it as the early part of the second half, described as "no change." Those are adjacent windows rather than contradictory ones, but the drift is in one direction and it is the second consecutive quarter of it.
8. Avidity's revenue or accretion: the deal closed inside the quarter, the cost is visible in a 322bps R&D drag and a $12.5B cash outflow, and there is still no revenue or accretion timeline for the DM1 and FSHD programmes.
9. How the Vanrafia readout is being framed: the release describes a positive difference in kidney-function decline at Week 136 with p = 0.057, which is a miss on the conventional threshold. The prepared remarks acknowledged it directly, and the release headline does not.
10. The ianalumab failure's placement: the warm autoimmune hemolytic anemia study missed statistical significance and the programme was dropped. That disclosure appeared inside a forward-looking readout slide rather than in the release's headline milestones, and drew no question.

Market Reaction

• Pre-print setup: NVS closed at $144.19 on April 27, up 4.6% year to date against the S&P 500's +4.8%, down 2.7% over the trailing 30 days and up 28.0% over the trailing twelve months. The 52-week closing range entering the print was $104.99 to $168.62, so the stock came in roughly 14% below its 52-week closing high after a soft month.
• Reaction session (before-open reporter, so the print day is the reaction day): opened at $144.26, essentially flat, traded a $142.65 to $145.65 range and closed at $145.50, up 0.9% or $1.31, on a session when the S&P 500 fell 0.5%.
• Intraday path: the ADR was quoted down 0.85% at $142.96 in the pre-market on the print, traded through the low end of the range during the European session and the US open, and recovered across and after the 8:00 AM ET call to finish positive.
• Volume: 2.7 million shares against a 30-day average of 1.6 million, 1.7 times normal.
• Listing divergence: the Swiss ordinary line closed the European session down 1.3% while the US ADR closed up 0.9%. The same divergence appeared at the February print, in the opposite direction.

This is a market that read a miss, sold it for two hours, listened to the call and bought it back. The specific thing that changed between the pre-market low and the close was not a number, because no number changed: it was the CFO's decomposition of the margin decline into three points of R&D and one point of generic mix, and the statement that three of the four transactions driving the R&D step-up enter the prior-year base from the second quarter. That converts the quarter from a margin problem into a phasing problem, and phasing problems trade differently.

The setup mattered as much as the print. Unlike February, when the stock went into results within 1.6% of a 52-week closing high after a 42% twelve-month run, this print landed on a stock down 2.7% over the prior month and 14% below its high. There was materially less to give back. A 0.9% close on 1.7 times volume, into a down tape, after a three-line miss, is a market that had already discounted the trough and was checking whether the second half was still intact.

The cross-listing divergence deserves the same reading it got in February, with the roles reversed. The Swiss holder saw an earnings miss and a further leg down in core profit. The ADR holder saw the same miss plus a currency tailwind and a multiple that had de-rated from 17.0x to 16.2x since the last print. Both are looking at the same company. The gap between them is the currency and the entry price.

Street Perspective

Debate: Is a guided miss still a miss?

Bull view: The bull case being made on the Street is that this quarter contained no new information. Every element of the shortfall, the fourteen points of generic drag, the R&D step-up, the lapping of a favourable prior-year gross-to-net adjustment, was described in February in the same terms and the same order. A miss against a consensus that failed to model a disclosed trough correctly is an estimate problem, not a company problem, and the reaffirmed guide is the tell.

Bear view: The bear camp contends that a pre-announced disappointment is still a disappointment. The company missed its own consensus on revenue, core operating income and core EPS simultaneously, the Entresto curve came in steeper than anyone modelled including management's own advisers, and the full-year guide now has less slack in it than it did in February because a weak Q1 must be made up in a second half that depends on launches rather than arithmetic.

Our take: The bulls have the better of the argument on the operating lines and the bears have the better of it on the guide's remaining slack. The margin decomposition is genuinely reassuring and the second-half base effect is genuinely mechanical. But the reaffirmation converts what had been a range into something close to a point estimate, and a company that reaffirms after missing has spent its buffer rather than replenished it.

Debate: Does the balance sheet matter yet?

Bull view: Some desks argue this is a non-issue. Net debt of $38.1B sits against an Aa3 and AA- credit, roughly 1.8 times core operating income and a business that generated $17.6B of free cash flow last year and $3.3B in a seasonally weak quarter. A pure-play innovator replacing the largest expiring base in its history should be levering up to buy late-stage assets, and the market should want it to.

Bear view: The bear camp points out that leverage doubled in ninety days, liquidity fell 40%, and the buyback that has quietly carried per-share growth is now returning 0.1 million net shares for $1.9B of cash. The February thesis rested partly on capital returns; that leg is materially weaker, and the M&A that replaced it has not yet produced a revenue line.

Our take: The bulls are right that this is not a credit question and the bears are right that it is an earnings-quality question. What concerns us is neither: it is that leverage nearly doubled and fourteen sell-side firms asked nineteen questions without touching it. A risk that no one is examining is not a risk that has been dismissed, it is a risk that has not been priced. We would rather own this after the question has been asked than before.

Debate: Is the pipeline optionality getting cheaper or riskier?

Bull view: A growing consensus view is that the optionality is getting cheaper. The multiple has come in from 17.0x to 16.2x trailing core earnings since February while the pipeline delivered a Phase III win across all three chronic inducible urticaria subtypes, a CHMP positive opinion, two-year kidney data published in a major journal with a priority review attached, a breakthrough designation and priority review in Sjögren's, and food-allergy Phase II data strong enough to trigger a Phase III start. Six or more pivotal readouts remain in the second half.

Bear view: The skeptics answer that the same quarter produced an outright Phase III failure in warm autoimmune hemolytic anemia, a primary endpoint that missed conventional significance in the ALIGN kidney study, a European regulatory withdrawal on the radioligand franchise, an accelerated-approval path now contingent on undisclosed regulator discussions, and a cardiovascular readout whose sponsor pre-commits to launching it "regardless of the relative risk reduction." Breadth is not the same as quality.

Our take: We hold the position we took in February and this quarter reinforces it: value the breadth, discount the headline. A portfolio with this many pivotal shots does not need any single one to land, and the remibrutinib stack in particular now has four credible indications where February had two. What the quarter did change is that the failures are now visible as well as the wins, and the base rate they imply argues for weighting the portfolio rather than the marquee asset. Three setbacks and five advances in a single quarter is roughly what a large late-stage pipeline should produce, which is a reason to hold it and not a reason to pay up for it.

Model Update Needed

Valuation: at the $145.50 close, NVS trades at 16.2x FY25 core EPS of $8.98 and 16.3x to 16.9x our unchanged FY26 core EPS range of $8.60 to $8.90. On FY25 IFRS EPS of $7.21 the trailing multiple is 20.2x. Market capitalisation of roughly $278B on 1,909M weighted average shares puts FY25 free cash flow of $17,596M at a 6.3% yield, up from 5.9% in February.

Valuation impact: the multiple has done roughly half of what we said in February it needed to do. At 17.0x trailing we said we wanted a mid-teens multiple or a de-risked cardiovascular readout before paying up; at 16.2x we are closer on the first and no further forward on the second. What has moved against the valuation in the same period is the balance sheet, where leverage has gone from 1.0x to 1.8x core operating income and the buyback has stopped translating cash into share count. Those two changes roughly offset. We continue to see fair value close to the current price, with the free cash flow yield the most attractive line in the case and the second-half inflection the thing that has to be observed rather than assumed.

Thesis Scorecard Post-Earnings

The pillars below are the ones established at initiation in February and are scored here against what this quarter's print and call revealed. They are not re-derived.

Status tag movements this quarter: Bear #4 moves from CONTAINED to EMERGING on the scale of the net-debt increase and the collapse of the buyback's per-share effect. Bull #1 strengthens within ON TRACK. Every other tag is unchanged: Bull #2 and Bull #3 stay ON TRACK, Bear #1 stays MATERIALIZING, and Bear #2 and Bear #3 stay EMERGING.

Overall: unchanged, with the operating case a little stronger and the financial case a little weaker. The growth portfolio did more of the work than it did last quarter and did it while absorbing the deepest generic drag the company will face. Against that, leverage nearly doubled, the buyback stopped converting cash into share count, and the one disclosure commitment carried over from February came back as a negative answer. Neither side moved enough to change the rating.

Action: Hold. Of the three conditions we set in February for an upgrade, one has moved and none has been met. The multiple is 16.2x trailing core EPS against 17.0x in February, closer to the mid-teens we asked for but not there. The first half is tracking to the guided decline rather than better than it. The cardiovascular readout is no more de-risked than it was and is now framed a few weeks later. The downgrade trigger, deceleration in the six-brand growth portfolio, moved emphatically the other way. We would want to see the second half actually inflect, or the balance-sheet question asked and answered, before paying up.